Following Monday’s clinical defeat by Eli Lilly, Novo Nordisk cut the 2027 list prices for its three GLP-1 medicines by as ...

Novo Nordisk and Vivtex Corporation have entered into a partnership to develop next-generation oral biologic medicines for ...

Eli Lilly (LLY) stock falls as rival Novo Nordisk (NVO) plans to cut Wegovy, Ozempic & Rybelsus U.S. list prices from Jan 1, ...

Novo Nordisk announced plans to drastically reduce the list price of its versions, Wegovy, Ozempic and Rybelsus.

Novo Nordisk is suing a Shrewsbury doctor who sells a cheaper compounded medicine version of its popular Ozempic and Wegovy weight-loss drugs.

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...

The FDA has approved the first-ever GLP-1 pill from Wegovy maker Novo Nordisk. Novo Nordisk said the starting dose of 1.5 milligrams will be available in early January in pharmacies and via ...

These two healthcare stocks are top names to invest in, but they haven't both been doing well of late. Eli Lilly has generated $25 billion in revenue from its fast-growing GLP-1 drugs this year.

Novo Nordisk's trial to treat Alzheimer's with its GLP-1 drug failed. The company has been losing market share to Eli Lilly. Novo Nordisk also lost a bidding war for a promising start-up.